Aims
Large-diameter metal-on-metal (MoM) total hip arthroplasty (THA) has demonstrated unexpected high failure rates and pseudotumour formation. The purpose of this prospective cohort study is to report ten-year results in order to establish revision rate, prevalence of pseudotumour formation, and relation with whole blood cobalt levels.

Methods
All patients were recalled according to the guidelines of the Dutch Orthopaedic Association. They underwent clinical and radiographical assessments (radiograph and CT scan) of the hip prosthesis and whole blood cobalt ion measurements. Overall, 94 patients (95 hips) fulfilled our requirements for a minimum ten-year follow-up.

Results
Mean follow-up was 10.9 years (10 to 12), with a cumulative survival rate of 82.4%. Reason for revision was predominantly pseudotumour formation (68%), apart from loosening, pain, infection, and osteolysis. The prevalence of pseudotumour formation around the prostheses was 41%, while our previous report of this cohort (with a mean follow-up of 3.6 years) revealed a 39% prevalence. The ten-year revision-free survival with pseudotumour was 66.7% and without pseudotumour 92.4% (p < 0.05). There was poor discriminatory ability for cobalt for pseudotumour formation.

Conclusion
This prospective study reports a minimum ten-year follow-up of large-head MoM THA. Revision rates are high, with the main reason being the sequelae of pseudotumour formation, which were rarely observed after five years of implantation. Blood ion measurements show limited discriminatory capacity in diagnosing pseudotumour formation. Our results evidence that an early comprehensive follow-up strategy is essential for MoM THA to promptly identify and manage early complications and revise on time. After ten years follow-up, we do not recommend continuing routine CT scanning or whole cobalt blood measurements, but instead enrolling these patients in routine follow-up protocols for THA.

Cite this article: Bone Jt Open 2022;3-1:61–67.

Keywords: metal-on-metal, pseudotumor, revision, total hip arthroplasty, hip replacement, metal ions, large head, surveillance
to be a general consensus not to use large-diameter MoM THA, there is much less consensus on the clinical management of our patients with MoM hip devices. In an attempt to identify ARMD early, worldwide regulatory authorities recommend regular patient follow-up, but guidelines for MoM THA follow-up differ considerably.\textsuperscript{9–11} This can partially be attributed to missing or conflicting evidence.\textsuperscript{12} We previously reported on the early results of an extensively screened prospective cohort of large-diameter MoM THA with a surprisingly high rate of soft-tissue reactions.\textsuperscript{4,5} This protocol was continued over the following years, with repeated annual follow-up and cross-sectional imaging in all patients. In this study, we present the results of the previously reported patient group in a concise follow-up.\textsuperscript{13}

**Methods**

Between January 2005 and November 2007, 116 patients (117 hips) were treated with large-head MoM THA for primary osteoarthritis (OA). Local ethics board approval and written informed consent were obtained. In this prospective study, patients were scheduled for an extensive screening protocol. The protocol consisted of an annual follow-up (including a physical examination and radiographs of the hip and pelvis), and CT scanning of the hip in all patients in 2010 (three to five years
postoperatively), followed by subsequent CT scans at five (if applicable) and ten years postoperatively. Blood samples for metal-ion analysis were collected according to accepted guidelines.14 We defined a pseudotumour as a solid/semi-solid or cystic periprosthetic soft-tissue mass eccentric to the joint with a minimum diameter of 2 cm that could not be attributed to infection, malignancy, bursa, or scar tissue.4 One radiologist evaluated all CT scans,15 and used a CT-grading system for postoperative CT findings in MoM THA.15 Cobalt ranges were set according to the recent guidelines: normal < 2 µg/l, intermediate 2 to 5 µg/l, elevated 5 to 10 µg/l, and extremely elevated > 10 µg/l.9,10,16,17 We used the bimetric porous-coated uncemented stem with a MoM M2a-Magnum femoral head and Recap acetabular component (Zimmer Biomet, USA). The system is modular, with increasing head size and concomitant larger shell size, plus the option to adapt the neck length using different length tapers. The main components of the head and acetabular component are produced from a cobalt-chromium alloy containing a small proportion of molybdenum and carbon. The stem and taper adapter are made of a titanium, aluminium, and vanadium alloy.4

**Table I. Patient characteristics.**

| Variable                          | All patients | Patients who completed ten-year follow-up | Revisions | Soft-tissue reaction, no revision | Soft-tissue reaction, no soft-tissue reaction |
|-----------------------------------|--------------|--------------------------------------------|-----------|-----------------------------------|-----------------------------------------------|
| Total patients, n (hips)          | 116 (117)    | 94 (95)                                    | 19 (19)   | 26 (26)                           | 49 (50)                                      |
| Sex, n (%)                        |              |                                            |           |                                   |                                               |
| Males                             | 54 (47)      | 44 (47)                                    | 5 (26)    | 14 (54)                           | 26 (53)                                      |
| Females                           | 62 (53)      | 50 (53)                                    | 14 (74)   | 12 (46)                           | 24 (47)                                      |
| Mean age at follow-up, yrs (range)| 70.2 (50 to 83) | 71.2 (50 to 83)                             | 67.8 (50 to 80) | 72.2 (50 to 82) | 71.9 (55 to 83) |
| Follow-up after index operation, yrs (range) | 9.6 (3.9 to 12.2) | 10.9 (10.1 to 12.2) | 11.0 (10.0 to 11.8) | 10.9 (9.9 to 11.8) | 10.9 (9.9 to 11.8) |
| Side, n (%)                       |              |                                            |           |                                   |                                               |
| Left                              | 41 (35.0)    | 32 (33.7)                                  | 4 (21)    | 8 (30.8)                          | 20 (40.0)                                    |
| Right                             | 76 (64.9)    | 63 (66.3)                                  | 15 (78.9) | 18 (69.2)                         | 30 (60.0)                                    |
| Pseudotumour, n (%)               | 44 (37.9)    | 39 (41.5)                                  | 13 (68.4) | 26 (100.0)                        | 0 (0.0)                                      |

**Fig. 2**

(a) Kaplan-Meier implant survival estimate for revision-free survival (all revision causes). (b) Kaplan-Meier implant survival analysis for pseudotumour and without pseudotumour (p = 0.005, log-rank test).
cut-off point for cobalt levels. A two-sided p-value < 0.05 was considered significant. Statistical software (SPSS Statistics, v. 23.0; IBM, USA) was used for all statistical analyses.

Results
The trial profile is listed in Figure 1. Initially, 116 patients (117) hips were included. Ultimately, 94 patients (95 hips) completed the ten-year follow-up period: however, 11 patients were lost to follow-up, one was revised prior the screening in 2010 for an infection, four refused further follow-up, and six patients died in the follow-up period due to unrelated reasons.

Patients and demographics. The cohort contained 54 males (55 hips) and 62 females (62 hips) with a mean age at index surgery of 60.1 years (38 to 72). All patients were diagnosed with primary OA. The characteristics of the 116 patients are shown in Table I. Mean follow-up after the index operation was 9.6 years (3.9 to 12.2).

CT scan evaluation. In 2010, all eligible patients (116 patients/117 hips) were evaluated with an initial (baseline) CT scan. As 24 patients were operated on between 2005 and 2006, the initial CT scan was the five-year follow-up scan; they were also scanned at ten years follow-up.

The remaining hips received the first CT scan in 2010, the second scan five years after the index operation, and a third scan ten years after the index operation. One patient was revised for an infection before 2010 and therefore did not receive a CT scan in 2010. Another 18 hips were revised between the five- and ten-year follow-up. Ultimately, the ten-year CT scan was performed in 77 hips.

Soft-tissue reaction. A total of 42 (39%) soft-tissue reactions met the criteria of a pseudotumour and were diagnosed in our previous study evaluating the initial CT scan of 2010. Of the 22 patients that were lost to follow-up, five (23%) had a pseudotumour and were excluded from further statistical analysis (Figure 1).

After comparing the CT scans at five and ten years, we found in four patients that there was regression of the pseudotumour, and in 19 patients that the pseudotumour remained unchanged. In one patient there was a progression of the pseudotumour. In two patients, there was a new symptomatic (painful) pseudotumour and one of them was subsequently revised. Between five and ten years of follow-up, 13 patients were revised for a pseudotumour. At ten years follow-up, we found 39 pseudotumours in 95 hips (41%).

Revisions. A total of 19 hips (16%) were revised during the ten-year follow-up: 13 for a symptomatic pseudotumour, three for pain without a pseudotumour, one for aseptic loosening, one for infection, and one for asymptomatic extensive progressive osteolysis. Mean time to revision was 4.7 years (2.1 to 7.7) after index operation.

Implant survival. In all, 13 hips were revised within three years after starting the screening protocol in 2010. Revision-free survival was 82.4% after ten years.
Revision-free survival after ten years with a pseudotumour was 66.7% and without a pseudotumour 92.4% (p = 0.005, log-rank test) (Figure 2).

**Metal ions analysis.** A total of 546 blood samples were analyzed, with a median of five samples per patient. The development of cobalt levels during the ten-year follow-up period is shown in Figure 3. Median level of cobalt at ten years follow-up was 5.3 µg/l (0.7 to 38.8; n = 48) in the group without a pseudotumour, 12.7 µg/l (0.6 to 105.9; n = 19) in the group with an unchanged pseudotumour, 7.2 µg/l (1.3 to 17.7; n = 2) in the group with progression of the pseudotumour, and 2.0 µg/l (0.9 to 4.9; n = 4) in the group with regression of the pseudotumour. ROC curve showed poor discriminatory ability for cobalt in predicting pseudotumour formation (Figure 4).

**Discussion**

In this study, we evaluated ten years of extensive monitoring of a prospectively followed cohort of patients with large-head MoM THA. Initial CT scan revealed a high incidence of pseudotumours. This resulted in an unacceptably high revision rate of 17.6% after ten years.

Sequential CT scans reveal progression of a soft tissue mass to be rare. Patients who did have a progressive lesion were found to have a symptomatic (painful) hip. Detectable pseudotumour formation therefore seems to develop early (within the first five years) after implantation.

There were only minor fluctuations in cobalt levels in patients with a level < 10 µg/l; fluctuations at a level > 10 µg/l were modest. Cobalt is a poor predictor for the presence of a pathological soft-tissue mass, and in our experience contributed little to the decision of whether or not to perform a hip revision. Different studies report on the survival of the M2a-Magnum articulation we used in this study, albeit with different stems.\textsuperscript{4,5,18-21} In our previous study, survival was 88% after 3.6 years.\textsuperscript{5} In a similar study conducted by Boland et al,\textsuperscript{22} a comparable survival of 92.4% was found after five years.

This study shows a revision-free survival of 82.4% after ten years. This survival rate is comparable to that reported by the four largest implant registries of MoM THA.\textsuperscript{6,12,23-25} Other studies report that in asymptomatic patients with normal blood metal ion levels (< 2 µg/l) and normal ultrasound imaging, the risk of progression of ultrasound findings is small within five years of initial assessment.\textsuperscript{26,27}

Besides the local effect of metal debris, there are concerns about possible systemic toxic effects of elevated levels of metal ions found in large-diameter MoM THA.\textsuperscript{28,29} Risk factors for elevated blood levels are malposition,
taper issues, and prosthesis design.30,31 Systemic metal ion levels decline after revision.

The MoM wear trend is biphasic. Run-in wear with a maximum of two years is followed by steady-state wear.12,13 The patients in our group were assumed to be in the steady-state wear because the extensive screening protocol started after a minimum of three years after the index operation. Our study adds evidence to the hypothesis that elevated blood metal ion levels, as reported by several institutions, have poor discriminant ability in predicting pseudotumour formation.26,27

In a study on MoM hip resurfacing, it was noted that the discriminatory capacity of cobalt alone was similar to cobalt and chromium combined, suggesting the limited utility of chromium ion levels.34 It was recommended that the decision for revision surgery cannot be made based on blood metal ion values. Most current guidelines advice against the use of systemic metal ions alone for the decision to revise a MoM hip prosthesis.10,11

We believe that the decision for revision should be based on the clinical scenario of symptoms, radiological findings, and, to a lesser extent, systemic metal ions. We trust the results of this study to be valid because we report on a unique prospective cohort of MoM THAs with an extensive screening protocol with clinical follow-up, elaborate imaging, and metal ion measurements during ten years of follow-up.

Limitations. Our study has several limitations. The number of included patients is small. Furthermore, the use of CT scan to detect soft-tissue masses around metal hip articulations is a subject of debate.34,35 Similarly to MRI, the usefulness of CT scan is largely dependent on the quality of the scanner and the implementation of metal artefact reduction algorithms. CT scan has the advantages of being more readily available than MRI, is fast and low-cost, and with the introduction of low-dose protocols the radiation dose is strongly reduced. Measuring implant orientation is much more reliable, and CT is superior to all other imaging methods in detecting osteolysis.35,36

In conclusion, this study reveals a high revision rate of large-head MoM THA after ten-year concise follow-up. Time to onset of symptoms, as well as development of soft-tissue reactions and raised metal ion levels, rarely exceeds four years post-implantation. This suggests that abnormalities occur in the early years after implantation and subsequently develop into a steady state. We therefore advise screening patients with cross-sectional imaging and metal ion levels within five years of implantation of a MoM hip prosthesis. In the absence of significant abnormalities on initial screening, we advise against the use of routine repeated cross-sectional imaging or measurement of systemic metal ions in asymptomatic patients.

Take home message
- The decision for revision a large-diameter metal-on-metal (MoM) total hip arthroplasty (THA) should be based on the clinical scenario of symptoms, radiological findings, and, to a lesser extent, systemic metal ions.
- In the absence of significant abnormalities on initial screening, routine repeated cross-sectional imaging or measurement of systemic metal ions in asymptomatic patients with a large-diameter MoM THA is not necessary.

References
1. Smith AJ, Dieppe P, Vernon K, Porter M, Blom AW. National Joint Registry of England and Wales. Failure rates of stemmed metal-on-metal hip replacements: analysis of data from the National Joint Registry of England and Wales. Lancet 2012;379(9812):1199–1204.
2. Smith AJ, Dieppe P, Howard PW, Blom AW. National Joint Registry for England and Wales. Failure rates of metal-on-metal hip resurfurcings: analysis of data from the National Joint Registry for England and Wales. Lancet 2012;380(9855):3014-6738(1202098)-1-1759-1766.
3. Pandit H, Glyn-Jones S, McLardy-Smith P, et al. Pseudotumours associated with metal-on-metal hip resurfurcings. J Bone Joint Surg Br 2008;90(8):847–851.
4. Bosker BH, Ettema HB, Boomsma MF, Kolien BJ, Maas M, Verheyen C. High incidence of pseudotumour formation after large-diameter metal-on-metal total hip replacement: a prospective cohort study. J Bone Joint Surg Br 2012;94-B(11):755–761.
5. Bosker BH, Ettema HB, van Rossum M, et al. Pseudotumor formation and serum ions after large head metal-on-metal stemmed total hip replacement. Risk factors, time course and revisions in 706 hips. Arch Orthop Trauma Surg 2015;135(3):417–425.
6. Australian Orthopaedic Association National Joint Replacement Registry. Hip and knee arthroplasty annual report. 2016. https://aoanjrr.sahmri.com/annual-reports-2016 (date last accessed 15 December 2021).
7. Matharu GS, Judge A, Murray DW, Pandit HG. Prevalence of and risk factors for hip resurfacing revision: a cohort study into the second decade after the operation. J Bone Joint Surg Am 2016;98(17):1444–1452.
8. Verheyen C, Verhaar J. Failure rates of stemmed metal-on-metal hip replacements. Lancet 2012;380(9837):105–106.
9. Medicines & Healthcare products Regulatory Agency. All metal-on-metal (MoM) hip replacements: updated advice for follow-up of patients. https://assets.publishing.service.gov.uk/media/5954ca1ded915d0baa00009b/MDA-2017-018_Final.pdf (date last accessed 15 December 2021).
10. US Food and Drug Administration. Medical devices: general recommendations for orthopaedic surgeons before metal-on-metal hip resurfacing surgery. https://www.fda.gov/medical-devices/metal-metal-hip-implants/information-orthopaedic-surgeons (date last accessed 15 December 2021).
11. Hannemann F, Hartmann A, Schmitt J, et al. European multidisciplinary consensus statement on the use and monitoring of metal-on-metal bearings for total hip replacement and hip resurfacing. Orthop Traumatol Surg Res 2013;99(3):S1877-0568(13)00027-3):263–271.:
2015;473(2):509–520. Clin Orthop Relat Res metal-on-metal total hip arthroplasty: dislocation infrequent but survivorship poor. High failure rates with a large-diameter hybrid metal-on-metal total hip replacement: clinical, radiological and retrieval analysis. J Bone Joint Surg Br. 2011;93-B(5):608–615. J Bone Joint Surg Br. 2008;31(12 Suppl 2). Systemic metal exposure in inflammatory pseudotumour formation following hip resurfacing. J Bone Joint Surg Am. 2009;91-B(12):1566–1574.

Kwon YM, Glyn-Jones S, Simpson DJ, et al. Analysis of wear of retrieved metal-on-metal hip resurfacing implants revised due to pseudotumours. J Bone Joint Surg Br. 2010;92-B(3):356–361.

Heisel C, Streich N, Krachler M, Jakubowicz E, Kretzer JP. Characterization of the running-in period in total hip resurfacing arthroplasty: in vivo and in vitro metal ion analysis. J Bone Joint Surg Am. 2009;90-A(Suppl 3):125–133.

Lee R, Essner A, Wang A. Tribological considerations in primary and revision metal-on-metal arthroplasty. J Bone Joint Surg Am. 2008;90-A(Suppl 3):118–124.

Hart AJ, Sabah S, Henckel J, et al. The painful metal-on-metal hip resurfacing. J Bone Joint Surg Br. 2009;81-B(6):738–744.

Wellenberg RHH, Ettema HB, Verheyen CCPM, Maas M, Boomsma MF. Cross sectional imaging of metal-on-metal hip arthroplasties. Acta Orthop. 2015;86(2):272–273.

Roth TD, Maertz NA, Parr JA, Beckwiler KA, Chaplin RH. CT of the hip prostheses: appearance of components, fixation, and complications. Radiographics. 2012;32(4):1089–1107.